CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

HC Wainwright issued their FY2029 EPS estimates for CG Oncology in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 ...

Full Year 2024 Results Key Financial Results Net loss: US$88.0m (loss widened by 30% ...

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...

EDT CG Oncology (CGON) files automatic mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

On Tuesday, Morgan Stanley initiated coverage on CG Oncology (NASDAQ:CGON) with an Overweight rating and a price target of $55.00.... On Wednesday, H.C. Wainwright initiated coverage on CG ...

March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...

Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology’s clinical trial program, including translational data, planned - Cretostimogene is an investigational ...